Lin Yichu, Chen Donglai, Ding Qifeng, Zhu Xuejuan, Zhu Rongying, Chen Yongbing
Department of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
Zhongguo Fei Ai Za Zhi. 2021 Jun 20;24(6):434-440. doi: 10.3779/j.issn.1009-3419.2021.102.19. Epub 2021 May 24.
Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer and one of the main causes of cancer-related deaths. In the past decade, with the widespread use of computed tomography (CT) in routine screening for lung cancer, the incidence of LUAD presenting as small pulmonary nodules radiologically, has increased remarkably. The mechanisms of the occurrence and progression of LUADs are complex, and the prognoses of patients with LUAD vary significantly. Although significant progress has been made in targeted therapy and immunotherapy for LUADs in recent years, the drug resistance of tumor cells has not been effectively overcome, which limits the benefits of patients. With the accomplishment of the Human Genome Project, sequencing-based genomic and transcriptomics have come into the field of clinical and scientific researches. Single-cell sequencing, as a new type of sequencing method that has captured increasing attention recently, can perform specific analysis of cell populations at single-cell level, which can reveal the unique changes of each cell type. Single-cell sequencing can also provide accurate assessment on heterogeneous stromal cells and cancer cells, which is helpful to reveal the complexity of molecular compositions and differences between non- and malignant tissues. To sum up, it is an urgent need for clinicians and basic scientists to deeply understand the pathogenesis and development of LUAD, the heterogeneity of tumor microenvironment (TME) and the mechanism of drug resistance formation through single-cell sequencing, so as to discover new therapeutic targets. In this paper, we reviewed and summarized the application and progress in single-cell sequencing of LUADs. .
肺腺癌(LUAD)是肺癌最常见的亚型,也是癌症相关死亡的主要原因之一。在过去十年中,随着计算机断层扫描(CT)在肺癌常规筛查中的广泛应用,影像学上表现为小肺结节的LUAD发病率显著增加。LUAD的发生和发展机制复杂,LUAD患者的预后差异很大。尽管近年来LUAD的靶向治疗和免疫治疗取得了显著进展,但肿瘤细胞的耐药性尚未得到有效克服,这限制了患者的获益。随着人类基因组计划的完成,基于测序的基因组学和转录组学进入了临床和科研领域。单细胞测序作为一种近年来越来越受关注的新型测序方法,能够在单细胞水平对细胞群体进行特异性分析,揭示每种细胞类型的独特变化。单细胞测序还能对异质性基质细胞和癌细胞进行准确评估,有助于揭示分子组成的复杂性以及非恶性组织与恶性组织之间的差异。综上所述,临床医生和基础科学家迫切需要通过单细胞测序深入了解LUAD的发病机制和发展、肿瘤微环境(TME)的异质性以及耐药性形成机制,从而发现新的治疗靶点。在本文中,我们回顾并总结了LUAD单细胞测序的应用及进展。